Following a year of unprecedented challenges for the pharmaceutical industry, it appears that change across the industry landscape is not slowing down in 2021. In this article forecasting the year ahead, our chief commercial officer, Tony O’Sullivan, talks to PharmTech about the disruption caused by the first wave of COVID-19 in pharmaceutical supply chain management, leading to many pharma companies taking steps towards supply chain localisation. He also touches on the impact of Brexit on the pharmaceutical industry and potential divergence between the UK and EU in terms of regulatory regimes, and the additional measures pharma companies will need to undertake to ensure compliance across markets.
